BusinessUS
AbbVie's $10.9 Billion Apogee Deal Is Really a Test of How Expensive the Humira Repair Job Still Is.
AbbVie's June 22, 2026 agreement to buy Apogee Therapeutics for $10.9 billion looks like one more biotech takeover. The sharper business read is that big pharma still has to pay dearly when a patent-cliff repair job depends on keeping its grip on immunology.